[{"id":"611d069e-ba56-4015-ba56-94bebd608133","acronym":"","url":"https://clinicaltrials.gov/study/NCT03839446","created_at":"2021-01-18T18:57:17.044Z","updated_at":"2025-02-25T13:52:47.649Z","phase":"Phase 2","brief_title":"Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy","source_id_and_acronym":"NCT03839446","lead_sponsor":"Robert Redner, MD","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2025-02-20"},{"id":"6280dfa5-ede9-4d89-a587-10249cd79abf","acronym":"AGORA-1","url":"https://clinicaltrials.gov/study/NCT05199051","created_at":"2022-01-20T15:53:56.079Z","updated_at":"2025-02-25T14:02:40.845Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML","source_id_and_acronym":"NCT05199051 - AGORA-1","lead_sponsor":"Centre Antoine Lacassagne","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/03/2023","start_date":" 06/03/2023","primary_txt":" Primary completion: 03/15/2027","primary_completion_date":" 03/15/2027","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2025-02-19"},{"id":"99225106-dfaa-4574-8f8a-c62a8252d206","acronym":"","url":"https://clinicaltrials.gov/study/NCT04293562","created_at":"2021-01-18T20:50:03.431Z","updated_at":"2025-02-25T15:11:29.634Z","phase":"Phase 3","brief_title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","source_id_and_acronym":"NCT04293562","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1186","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"5a8a1ba9-7750-4d42-886f-26c4d198762e","acronym":"NCI-2018-01812","url":"https://clinicaltrials.gov/study/NCT03672539","created_at":"2021-01-18T18:00:52.647Z","updated_at":"2025-02-25T15:43:12.491Z","phase":"Phase 2","brief_title":"Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03672539 - NCI-2018-01812","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-10"},{"id":"5adabdf3-1484-4c8e-ac66-a9230e113fb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04915612","created_at":"2021-06-07T15:53:27.598Z","updated_at":"2025-02-25T15:35:05.555Z","phase":"Phase 1","brief_title":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04915612","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-10"},{"id":"610f01eb-c68e-44f8-9b23-e46ae4e5528c","acronym":"GO-TAG","url":"https://clinicaltrials.gov/study/NCT05716009","created_at":"2023-02-08T18:00:15.099Z","updated_at":"2025-02-25T15:27:53.038Z","phase":"Phase 1","brief_title":"Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML","source_id_and_acronym":"NCT05716009 - GO-TAG","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/25/2027","primary_completion_date":" 12/25/2027","study_txt":" Completion: 12/25/2028","study_completion_date":" 12/25/2028","last_update_posted":"2025-02-10"},{"id":"d48274bb-de2d-4319-b258-4def71b8a13e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05558124","created_at":"2022-09-28T14:56:07.027Z","updated_at":"2025-02-25T16:33:08.602Z","phase":"Phase 1","brief_title":"CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML","source_id_and_acronym":"NCT05558124","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/16/2023","start_date":" 02/16/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-07"},{"id":"cfc49a74-4ea2-4c0c-b519-268b184b6efd","acronym":"SWOG-S0703","url":"https://clinicaltrials.gov/study/NCT00658814","created_at":"2021-01-29T06:58:25.253Z","updated_at":"2025-02-25T16:43:30.772Z","phase":"Phase 2","brief_title":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT00658814 - SWOG-S0703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"3e6558d8-f022-4465-b340-329db64b8a39","acronym":"VBP101","url":"https://clinicaltrials.gov/study/NCT04849910","created_at":"2021-04-19T11:53:06.069Z","updated_at":"2025-02-25T17:01:02.310Z","phase":"Phase 1/2","brief_title":"Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS","source_id_and_acronym":"NCT04849910 - VBP101","lead_sponsor":"Vor Biopharma","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • tremtelectogene empogeditemcel (VOR33)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-03"},{"id":"8f439945-e5eb-40b9-a7e6-6eb64cdd7790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409161","created_at":"2021-01-18T05:47:46.957Z","updated_at":"2025-02-25T17:35:27.084Z","phase":"Phase 2","brief_title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT01409161","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 10/05/2011","start_date":" 10/05/2011","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 12/18/2025","study_completion_date":" 12/18/2025","last_update_posted":"2025-01-28"},{"id":"e50a0a5e-dc78-4e71-99c4-1a70effa128a","acronym":"APAL2020D","url":"https://clinicaltrials.gov/study/NCT05183035","created_at":"2022-01-10T14:58:22.318Z","updated_at":"2024-07-02T16:34:59.534Z","phase":"Phase 3","brief_title":"Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05183035 - APAL2020D","lead_sponsor":"LLS PedAL Initiative, LLC","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • Mylotarg (gemtuzumab ozogamicin) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2032","study_completion_date":" 02/01/2032","last_update_posted":"2024-06-03"},{"id":"d2f2a1f1-7bb1-4919-a610-7815b806ac30","acronym":"NCI-2019-01726","url":"https://clinicaltrials.gov/study/NCT03900949","created_at":"2021-01-18T19:12:29.931Z","updated_at":"2024-07-02T16:35:01.958Z","phase":"Phase 1","brief_title":"Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03900949 - NCI-2019-01726","lead_sponsor":"Uma Borate","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" CD33 positive • CD33 expression","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Suspended","enrollment":" Enrollment 18","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-22"},{"id":"88461e0e-9239-461f-831e-38bf1a8c7c20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04207190","created_at":"2021-01-18T20:29:32.215Z","updated_at":"2024-07-02T16:35:05.019Z","phase":"Phase 1","brief_title":"Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04207190","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-08"},{"id":"eae87f81-b151-4534-856f-6fe520d9c93c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04793919","created_at":"2024-04-15T17:24:45.119Z","updated_at":"2024-07-02T16:35:09.764Z","phase":"Phase 2","brief_title":"Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT04793919","lead_sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 10/09/2019","start_date":" 10/09/2019","primary_txt":" Primary completion: 10/09/2025","primary_completion_date":" 10/09/2025","study_txt":" Completion: 10/10/2027","study_completion_date":" 10/10/2027","last_update_posted":"2024-04-15"},{"id":"59506a1f-78d0-44c7-9ec4-22c51f22d853","acronym":"","url":"https://clinicaltrials.gov/study/NCT04050280","created_at":"2021-01-18T19:51:44.499Z","updated_at":"2024-07-02T16:35:11.259Z","phase":"Phase 2","brief_title":"CLAG-GO for Patients With Persistent, Relapsed or Refractory AML","source_id_and_acronym":"NCT04050280","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Mylotarg (gemtuzumab ozogamicin) • cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-04-05"},{"id":"65b8b469-ba1f-453c-992d-ec880c54605c","acronym":"NCI-2018-01613","url":"https://clinicaltrials.gov/study/NCT03737955","created_at":"2021-01-18T18:18:29.778Z","updated_at":"2024-07-02T16:35:12.661Z","phase":"Phase 2","brief_title":"Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03737955 - NCI-2018-01613","lead_sponsor":"University of Washington","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/30/2018","start_date":" 11/30/2018","primary_txt":" Primary completion: 03/15/2023","primary_completion_date":" 03/15/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-27"},{"id":"7e5df265-735a-4b50-970f-ba82acf13b08","acronym":"","url":"https://clinicaltrials.gov/study/NCT05189639","created_at":"2022-01-12T14:53:46.362Z","updated_at":"2024-07-02T16:35:19.384Z","phase":"","brief_title":"A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05189639","lead_sponsor":"Pfizer","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 11/17/2027","primary_completion_date":" 11/17/2027","study_txt":" Completion: 11/17/2027","study_completion_date":" 11/17/2027","last_update_posted":"2024-02-14"},{"id":"417e8b04-49ba-41fb-98db-3a2a6390d025","acronym":"","url":"https://clinicaltrials.gov/study/NCT04070768","created_at":"2021-01-18T19:55:46.986Z","updated_at":"2024-07-02T16:35:26.408Z","phase":"Phase 1","brief_title":"Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113","source_id_and_acronym":"NCT04070768","lead_sponsor":"John Quigley","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" CD33 expression","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/06/2019","start_date":" 09/06/2019","primary_txt":" Primary completion: 10/12/2023","primary_completion_date":" 10/12/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-12-13"},{"id":"462f5567-5e14-4156-bbc3-44f34a136751","acronym":"","url":"https://clinicaltrials.gov/study/NCT02221310","created_at":"2021-01-18T10:24:38.708Z","updated_at":"2024-07-02T16:35:31.548Z","phase":"Phase 2","brief_title":"Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS","source_id_and_acronym":"NCT02221310","lead_sponsor":"New York Medical College","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/07/2011","start_date":" 12/07/2011","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2023-10-26"},{"id":"6a7383f9-1e51-45e9-9cb1-1708edc28ea2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02117297","created_at":"2021-01-18T09:48:00.874Z","updated_at":"2024-07-02T16:35:31.643Z","phase":"Phase 2","brief_title":"SCT Plus Immune Therapy in Average Risk AML/MDS","source_id_and_acronym":"NCT02117297","lead_sponsor":"New York Medical College","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/12/2012","start_date":" 01/12/2012","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2023-10-26"},{"id":"629a9570-5526-4e21-a561-e5d4879b487d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03390296","created_at":"2021-01-18T16:43:54.834Z","updated_at":"2024-07-02T16:35:38.199Z","phase":"Phase 1/2","brief_title":"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03390296","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Bavencio (avelumab) • azacitidine • Mylotarg (gemtuzumab ozogamicin) • Daurismo (glasdegib) • ivuxolimab (PF-04518600)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 02/04/2022","primary_completion_date":" 02/04/2022","study_txt":" Completion: 02/04/2022","study_completion_date":" 02/04/2022","last_update_posted":"2023-09-04"},{"id":"ea424ad4-9fe1-4d9d-bea7-2fc6acf46bfb","acronym":"VINCENT","url":"https://clinicaltrials.gov/study/NCT05904106","created_at":"2023-06-15T18:09:01.706Z","updated_at":"2024-07-02T16:35:40.488Z","phase":"Phase 2","brief_title":"Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML","source_id_and_acronym":"NCT05904106 - VINCENT","lead_sponsor":"Technische Universität Dresden","biomarkers":" ABL1 • NPM1 • CD33","pipe":" | ","alterations":" NPM1 mutation • CD33 positive","tags":["ABL1 • NPM1 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2023-08-09"},{"id":"f066ba35-63f6-465c-8eac-446af1756f24","acronym":"MOSAIC","url":"https://clinicaltrials.gov/study/NCT04385290","created_at":"2021-01-18T21:10:20.677Z","updated_at":"2025-02-25T15:43:59.383Z","phase":"Phase 1/2","brief_title":"Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","source_id_and_acronym":"NCT04385290 - MOSAIC","lead_sponsor":"Technische Universität Dresden","biomarkers":" FLT3 • RUNX1 • RUNX1T1","pipe":" | ","alterations":" CD33 expression","tags":["FLT3 • RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 09/04/2020","start_date":" 09/04/2020","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-08-09"},{"id":"2ed79be2-2023-4696-88ba-ba835e740c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005962","created_at":"2021-01-17T23:52:00.807Z","updated_at":"2024-07-02T16:35:45.247Z","phase":"Phase 2","brief_title":"Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia","source_id_and_acronym":"NCT00005962","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • topotecan • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 10/04/2000","start_date":" 10/04/2000","primary_txt":" Primary completion: 10/01/2005","primary_completion_date":" 10/01/2005","study_txt":" Completion: 06/01/2007","study_completion_date":" 06/01/2007","last_update_posted":"2023-06-22"}]